File:MTBVAC development 25 years.png
From Wikimedia Commons, the free media repository
Jump to navigation
Jump to search
Size of this preview: 800 × 488 pixels. Other resolutions: 320 × 195 pixels | 640 × 390 pixels | 1,024 × 625 pixels | 1,562 × 953 pixels.
Original file (1,562 × 953 pixels, file size: 523 KB, MIME type: image/png)
File information
Structured data
Captions
Summary
[edit]DescriptionMTBVAC development 25 years.png |
English: Figure 3. MTBVAC from discovery to human clinical evaluation abiding by Pasteur’s principles on vaccine development. Identification of virulence genes phoP and of PDIM locus in M. tuberculosis (1997-2001) settled the basis for MTBVAC construction (2005-2008). 2001 until present: ongoing preclinical characterization studies deciphering mechanisms of vaccine safety and induced protection in different recognized TB-relevant animal models conducted by different national and international laboratories: mouse studies (Unizar) and other laboratories in Spain), guinea pigs (Public Health England (PHE)) and non-human primates (PHE and Biomedical Primate Research Center (BPRC) 2008-2012: GMP development of freeze-dried MTBVAC. 2012 until present: Industrial development and scale-up production of MTBVAC. 2012: First-in-human Phase 1a clinical evaluation of MTBVAC in healthy adults in Lausanne, Switzerland (funded by TBVI). 2015: successful Phase 1a completion leads to first-in-human Phase 1b evaluation of MTBVAC in newborns in South Africa in collaboration with the South African Tuberculosis Vaccine Initiative (SATVI) (NORAD funding). 2019: MTBVAC enters two dose-defining Phase 2 trials in South Africa, one in adults (in collaboration with IAVI, US) and another one in newborns (EDCTP2-funded), which includes capacity building studies in Senegal and Madagascar. 2021: MTBVAC received EDCTP funding for a Phase 3 efficacy evaluation in newborns in South Africa, Senegal and Madagascar. BIOFABRI is the exclusive licensee of MTBVAC and industrial developer and Sponsor of MTBVAC clinical trials. University of Zaragoza (Unizar) is MTBVAC intellectual rights owner and vaccine discoverer, and TBVI is the European Tuberculosis Vaccine Initiative and IAVI is the International AIDS Vaccine Initiative. Since 2008, BIOFABRI works in close collaboration with Unizar and TBVI in the GMP and clinical development of MTBVAC. In 2020, IAVI collaborations were initiated. |
Date | |
Source | Own work |
Author | MTBVAC |
Licensing
[edit]I, the copyright holder of this work, hereby publish it under the following license:
This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the same or compatible license as the original.
File history
Click on a date/time to view the file as it appeared at that time.
Date/Time | Thumbnail | Dimensions | User | Comment | |
---|---|---|---|---|---|
current | 10:37, 16 November 2021 | 1,562 × 953 (523 KB) | DesiVM2017 (talk | contribs) | Cross-wiki upload from en.wikipedia.org |
You cannot overwrite this file.
File usage on Commons
There are no pages that use this file.
Metadata
This file contains additional information such as Exif metadata which may have been added by the digital camera, scanner, or software program used to create or digitize it. If the file has been modified from its original state, some details such as the timestamp may not fully reflect those of the original file. The timestamp is only as accurate as the clock in the camera, and it may be completely wrong.
Horizontal resolution | 59.06 dpc |
---|---|
Vertical resolution | 59.06 dpc |
Hidden categories: